Shots:

• Pfizer’s to receive $75M up front- $365M development & commercial milestones and royalties on sales of the product. Biogen plans to develop Pfizer’s PF-05251749 for Sundowning in AD and Irregular Sleep-Wake Rhythm Disorder (ISWRD) in PD
• The acquisition of PF-05251749 complements Biogen’s existing pipeline therapies in AD & PD. The transaction is expected to be closed in Q1’20
• PF-05251749 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms in neurological diseases with the expected initiation of P-Ib study in Q4’20

Click here to­ read full press release/ article 

| Ref: GlobeNewswire | Image: Biogen